Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948605 · ClinicalTrials.gov registry record · NA
EMPOWER AUD Pivotal Trial
A NA study of Alcohol Use Disorder and Alcoholism, sponsored by Theranova, L.L.C..
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05948605: Completed NA study of Alcohol Use Disorder and Alcoholism, sponsored by Theranova, L.L.C..
NCT05948605 is a NA study of Alcohol Use Disorder and Alcoholism that has completed, run by Theranova, L.L.C.. The registered enrollment target is 35 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948605, a NA study of Alcohol Use Disorder and Alcoholism, has completed, sponsored by Theranova, L.L.C..
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multi-site, double-blinded, prospective, randomized, sham-controlled study
Primary Outcome
The primary safety endpoint will be comparing the frequency of device-related Serious AEs (SAEs) between the Active and Sham Treatment groups, where device-related SAEs include probably and possibly device-related serious adverse events
Conditions Studied
Interventions
- DEVICE Empower Neuromodulation System
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2025-08-06 |
| Phase | NA |
What the finished NCT05948605 record still lists
NCT05948605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Empower Neuromodulation System is the first listed.
NCT05948605 reports a single indexed study location in California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05948605 about?
NCT05948605 is a clinical study titled "EMPOWER AUD Pivotal Trial". Multi-site, double-blinded, prospective, randomized, sham-controlled study
What is the current status of trial NCT05948605?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2023-12-01. Estimated completion is 2025-08-06.
What conditions does trial NCT05948605 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Alcoholism, Alcohol Abuse.
What interventions are being tested in trial NCT05948605?
The interventions under investigation include: Empower Neuromodulation System (DEVICE).
Who is sponsoring clinical trial NCT05948605?
This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948605 being conducted?
This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05948605's enrollment target sits among peer trials
35 147th of 184 higher than 37 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI